Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers
Zingg, A.; Ritschard, R.; Thut, H.; Buchi, M.; Holbro, A.; Oseledchyk, A.; Heinzelmann, V.; Buser, A.; Binder, M.; Zippelius, A.; Mantuano, N. R.; Laubli, H.
Show abstract
CAR-T cell therapy has provided a significant improvement for patients with chemotherapy-resistant B cell malignancies. However, CAR-T cell treatment of patients with solid cancers has been more difficult, in part because of the heterogeneous expression of tumor-specific cell surface antigens. Here, we describe the generation of a fully human CAR targeting altered glycosylation in secretory epithelial cancers. The expression of the target antigen - the truncated, sialylated O-glycan sialyl-Thomsen-Nouveau antigen (STn) - was studied with a highly STn-specific antibody across various different tumor tissues. Strong expression was found in a high proportion of gastro-intestinal cancers including pancreatic cancers and in gynecological cancers, in particular ovarian and endometrial tumors. T cells expressing anti-STn CAR were tested in vitro and in vivo. Anti-STn CAR-T cells showed activity in mouse models as well as in assays with primary ovarian cancer samples. No significant toxicity was observed in mouse models, although some intraluminal expression of STn was found in gastro-intestinal mouse tissue. Taken together, this fully human anti-STn CAR construct shows promising activity in preclinical tumor models supporting its further evaluation in early clinical trials.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 96%
- GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma 96%
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies 95%
Similar papers in this journal
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting 96%
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy 96%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 95%
Similar papers in this journal
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 96%
- CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade 96%
- EphA2 and Phosphoantigen-Mediated Selective Killing of Medulloblastoma by γδT Cells Preserves Neuronal and Stem Cell Integrity 96%
Similar papers in this journal
- Enhanced anti-tumor activity by Zinc Finger Repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs 97%
- Installation of Dominant-Negative Mutations in FAS and TGFβR2 via Base Editing in Primary T Cells 96%
- Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases 92%
Similar papers in this journal
- A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) 95%
- Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications in a common base culture media system 95%
- A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.